Page 160 WHO - Guidelines on the pharmacological treatment of persisting pain in children with medical illness

cognitive behaviour therapy (GRADE profiles) 122 other types of pain (Rec. 16) 46, 94, 147
cognitive behaviour therapy or relaxation distribution 137
in chronic and recurrent non-headache pain 122 dosage limit 41
systematic review 122 dosage table
Commission on Narcotic Drugs (CND) 131 opioid-naive children 49
comprehensive approach 37, 146 opioid-naive infants 48
constipation 41 opioid-naive neonates 48
consumption level oral/parenteral conversion 50
morphine dose increase
global 133 in inpatient settings 64–80
strong opioid analgesics 133 in outpatient settings 64–80
contributors to publication 141–145 dosing at regular intervals 37, 146
consultants 143 dysesthesia 19
declarations of interest 143–145
World Health Organization Secretariat 142
controlled medicines E
definition 8 education of health professionals
controlled substances (Rec. 20) 59–60, 123–124, 147
definition 8 EMLc 42
Convention on Psychotropic Substances 131 acronym 7
conventions, international drug control enzyme CYP2D6
Convention against Illicit Traffic in Narcotic Drugs definition 8
and Psychotropic Substances, United Nations 131 role in codeine metabolism 39
Convention on Psychotropic Substances, ERP acronym 7
United Nations 131 evidence retrieval and appraisal 104–127
definition 9 GRADE profiles 105–122
list 131 cognitive behaviour therapy or relaxation 122
Single Convention on Narcotic Drugs 131–138 epidural morphine versus epidural fentanyl
competent national authorities 133 or epidural hydromorphone in post-operative
domestic production 134–135 pain for orthopaedic surgery 110
drug misuse versus patient need 132 fentanyl, nebulized versus fentanyl IV in acute
ensure availability of narcotic drugs 132 pain 120
estimates fentanyl, transdermal in cancer pain 121
INCB/WHO manual 134
market availability of controlled ibuprofen versus codeine in musculoskeletal
substances 134 trauma 106
need exceeding ~ 133–134 intranasal fentanyl versus morphine IV in acute
supplementary 134 pain of bone fractures 108
import/export authorizations or certificates 136 IV morphine PCA versus hydromorphone PCA
importation/exportation of narcotic drugs 135 in mucositis pain 107
medicines regulatory authority 133 morphine PCA
ministry of health 133 versus ketobemidone PCA in post-operative
prescribing and dispensing requirements 138 pain 113
relief of pain and suffering 132 versus morphine IM in post-operative
reporting system 137 pain 117
Schedule I 132, 133 morphine PCA with background infusion versus
conversion table 50 morphine as continuous infusion in
corticosteroids post-operative pain 118
as adjuvant 50, 95, 147 morphine versus buprenorphine in post-operative
clinical question 95 pain after orthopaedic surgery 111
Recommendation 18 50, 95, 147 morphine, oral
in cancer pain 116
versus morphine IV continuously in sickle
D cell episodes 119
declarations of interest oral transmucosal fentanyl citrate versus
external reviewers 144 intravenous morphine in extremity injury
Guidelines Development Group 143–144 or suspected fracture 109
diabetic neuropathy 51 oxycodone versus ibuprofen or oxycodone/
disease-specific therapies 13 ibuprofen in orthopaedic injury pain 115
dispersible tablets (oral solid formulation; definition) 8 oxycodone, buccal versus placebo in abdominal
distinction between breakthrough pain and pain 114

157 <